Ibogaine: The Molecule, The Plant, and The Promise

This episode establishes the series through a narrative arc of discovery and suppression. Beginning with the Bwiti spiritual tradition in Gabon and the cultural significance of the iboga plant, the hosts trace Western scientific isolation of ibogaine in the early 1900s and its brief mid-century use as a stimulant tonic. The episode centers on the Howard Lotsof story — the 1962 accidental discovery of anti-addiction activity — and the patient-advocate movement that followed. It concludes by explaining U.S. Schedule I status and the rise of offshore clinics, then pivots to the modern psychedelic-medicine wave, state initiatives, and federal interest, finally laying out the ten-episode journey ahead.

The second episode grounds the listener in botanical and chemical fundamentals. It covers Tabernanthe iboga taxonomy, morphology, and why the root bark concentrates alkaloids. The hosts map the iboga-alkaloid family — ibogaine, ibogamine, tabernanthine, ibogaline, coronaridine, and voacangine — highlighting the shared isoquinuclidine fused to indole skeleton. Biosynthesis via the monoterpene indole alkaloid (MIA) pathway is explained from strictosidine through the iboga-type skeleton. The episode concludes by addressing alkaloid distribution across tissues and variability by provenance, setting up the sourcing and quality themes that follow.

This episode reveals why the plant everyone talks about is not the one industry actually uses. The discussion contrasts T. iboga — with its low yield, slow growth, and conservation pressures — against Voacanga africana, which dominates the alkaloid trade due to high voacangine content. The strategic chemistry of converting voacangine to ibogaine via ester hydrolysis and decarboxylation is explained at the level of approach and significance. CITES status and Gabonese heritage controls are addressed, as is the sustainability argument for Voacanga. The episode closes with implications for impurity fingerprints and sourcing for future clinical programs.

Episode 4 follows raw material from field to feedstock, examining the agronomy of both source species and why cultivating iboga is genuinely difficult. The discussion covers wild collection versus cultivation in West Africa, the ethics of heritage and benefit-sharing under the Nagoya Protocol, and conservation pressures from overharvest. From a supply-security perspective appropriate to a future approved drug, the hosts address what a CDMO must grapple with. The episode concludes with emerging non-agricultural routes — plant cell culture and synthetic-biology production of iboga alkaloids — offering a forward-looking path to de-risking supply.

This episode bridges chemistry and quality by explaining how ibogaine is separated from plant material and purified to an API specification. Acid-base alkaloid partitioning and the distinction between crude total-alkaloid extract and purified ibogaine HCl form the conceptual foundation. Analytical identity and purity — via HPLC/UPLC, LC-MS, and NMR — are covered as orthogonal controls. Impurity profiling is addressed in detail: plant-related congeners, noribogaine, and process-related impurities. The episode emphasizes GMP specification thinking (assay, related substances, residual solvents, heavy metals) and the real-world harm driven by uncharacterized underground material.

Episode 6 is a synthesis seminar: it explains the iboga skeleton as a classic synthetic challenge and surveys landmark and modern approaches. Buechis 1966 total synthesis is framed as the reference point, with modern asymmetric and step-economical routes explained at the level of strategy and key bond-forming ideas (e.g., Diels-Alder construction of the isoquinuclidine). The industrial semi-synthesis from voacangine is discussed strategically, as is its access to noribogaine. The hosts explain how synthetic strategy enabled next-generation analogs and address the realities of total versus semi-synthesis economics at scale. The episode concludes with a bridge: we can make it — now what does it do?

This episode delivers the definitive mechanistic tour: ibogaine is a textbook "dirty drug" acting across many targets. The hosts enumerate its bindings — NMDA antagonism, α3β4 nicotinic acetylcholine receptor antagonism (the leading anti-addiction hypothesis), κ- and μ-opioid activity, σ1/σ2, and SERT/monoamines — and weigh their relative importance. Neurotrophic effects (GDNF/BDNF) and the psychoplastogen concept are introduced. Noribogaine, the long-lived O-demethylated metabolite, is given equal weight, with CYP2D6 polymorphism explaining interindividual exposure variability. The discussion of pharmacokinetics — lipophilicity, accumulation, duration — ties mechanism to the observed addiction-interruption phenomenon and bridges to the safety episode that follows.

Episode 8 is the series safety cornerstone. Cardiotoxicity is introduced as the single biggest barrier to ibogaine becoming an approved medicine. The mechanism is explained at the channel level: hERG (Kv11.1) potassium-channel blockade leads to delayed repolarization, QTc prolongation, and potentially fatal torsades de pointes. The hosts address why the risk window is extended (given the long half-lives of both parent and noribogaine), enumerate risk factors (baseline QT, hypokalemia/hypomagnesemia, bradycardia, drug interactions), and highlight the special vulnerabilities of the opioid-detox population. The real-world death record is reviewed honestly. Mitigation science — cardiac screening and monitoring, electrolyte optimization, and the magnesium co-administration hypothesis from the Stanford MISTIC study — is covered as the practical framework for risk reduction.

Episode 9 tells the medicinal-chemistry redemption arc: how chemists tried to retain ibogaines therapeutic core while deleting cardiotoxicity and the multi-hour hallucinogenic experience. 18-methoxycoronaridine (18-MC) is presented as a selective α3β4 antagonist that sidesteps hERG and serotonergic hallucinogenic activity. Tabernanthalog, the function-oriented simplification from the Olson lab, is examined in detail — including its non-hallucinogenic, non-cardiotoxic profile, rodent efficacy for alcohol- and heroin-seeking, and clinical progression under Delix Therapeutics. The psychoplastogen thesis (the argument that the therapeutic effect may be separable from the psychedelic experience) is presented with its scientific pushback. SAR lessons and other ibogalogs (DemeRx/atai programs, noribogaine studies) are covered, with accurate pipeline status grounded to sources.

The series capstone maps the full clinical landscape. The hosts review primary and secondary indications — opioid use disorder (the flagship), other substance use disorders (cocaine, alcohol, methamphetamine, nicotine), PTSD, TBI, and depression — with mechanistic rationale for each. An honest read of the evidence base is provided: decades of observational and offshore-clinic data exist, but randomized controlled trials are scarce. The landmark Stanford MISTIC magnesium-ibogaine study in special-operations veterans is analyzed for design, findings, and caveats. Current and future programs are detailed — DemeRx/atai (DMX-1002) for OUD, continued Stanford work, the Texas UTHealth-UTMB consortium (SB 2308), Oregon admitteds supervised-access law, and federal interest — all grounded to sourced information. Regulatory and manufacturing realities (Schedule I friction, cardiac safety as the gating issue, the GMP-supply burden) are addressed. The episode closes by synthesizing the entire ten-episode narrative and delivering a balanced verdict: real promise, real peril, real evidence gaps, and why the next few years are decisive.

Episode 11 steps outside the sterile pharmaceutical framework to examine Tabernanthe iboga and Voacanga africana as dynamic, living biological systems within equatorial West Central African ecosystems. Rather than viewing these plants merely as industrial feedstocks, this bonus deep-dive explores their evolutionary logic, forest-floor ecology, tissue-specific biochemistry, and the intricate biosynthetic pathways behind monoterpene indole alkaloids (MIAs)

Overview

In this deep-dive episode, we explore the fascinating multi-decade journey of ketanserin tartrate—a molecule discovered at Janssen Pharmaceutica in 1980 that bridges cardiovascular pharmacology and modern psychedelic neuroscience[1]. Originally developed as a selective serotonin receptor antagonist for cardiovascular disorders, ketanserin has re-emerged in scientific literature as a pivotal candidate for a purpose-built "trip killer" and rescue agent in psychedelic-assisted therapy[4].

Key Highlights & Topics Covered

• The Molecule & Synthesis: An introduction to ketanserin's novel architecture—joining a quinazolinedione heterocycle with a 4-fluorobenzoylpiperidine fragment—and its discovery as the first selective 5-HT2A serotonin receptor antagonist[2].
• Clinical History & Overseas Legacy: A review of its clinical usage outside the United States under brand names such as Sufrexal and Ketensin for arterial hypertension, Raynaud's phenomenon, and topical wound-healing formulations[3].
• Pharmacological Profile: A detailed breakdown of its high-affinity competitive antagonism at 5-HT2A receptors, along with secondary actions at alpha-1 adrenergic and H1 histamine receptors[15].
• Why It’s Not in the US Pharmacopeia: An investigation into why ketanserin was never approved by the US FDA, focusing on its dose-dependent QTc interval prolongation driven by hERG potassium channel blockade[2], and how the 1980s market entry of ACE inhibitors and calcium channel blockers sidelined its US commercialization[20][21].
• The "Naloxone for the Mind" Breakthrough: How research evolved from Vollenweider’s 1998 trial proving 5-HT2A activation mediates psilocybin’s psychedelic effects[23][24] to Becker et al.’s 2023 University of Basel clinical trial showing that administering ketanserin during an LSD trip reduces acute session duration from 8.5 hours to 3.5 hours[4].
• Future in Psychedelic-Assisted Therapy: Why a mechanistically targeted 5-HT2A antagonist offers clinicians a cleaner, single-receptor safety net and abortive tool compared to off-label antipsychotics or sedatives[4].

Target Audience

Designed to bring both seasoned pharmaceutical researchers and casual listeners up to speed on the history, mechanism, safety profile, and clinical potential of ketanserin in modern neuropsychiatry